MannKind - Public Comps and Valuation Multiples

MannKind Overview

About MannKind

MannKind Corp is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. Its approved product, Afrezza (insulin human) Inhalation Powder, is an ultra-rapid-acting inhaled insulin used to improve glycemic control in adults with diabetes. The product consists of a dry powder formulation of human insulin delivered from a small portable inhaler.

Founded

1991

HQ

Employees

407

Website

mannkindcorp.com

Sectors

Drug Development & Therapeutics
Drug Delivery Systems
BioTech

Financials

LTM Revenue $295M

LTM EBITDA n/a

EV

$1.3B

Valuation Multiples

Multiples.vc

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

MannKind Financials

MannKind has a last 12-month revenue of $295M and a last 12-month EBITDA of n/a.

In the most recent fiscal year, MannKind achieved revenue of $286M and an EBITDA of $77.5M.

MannKind expects next 12-month revenue of XXX and NTM EBITDA of XXX

See MannKind valuation multiples based on analyst estimates

MannKind P&L

	FY 2023	FY 2024	FY 2025	LTM	NTM
Revenue	$199M	$286M	XXX	XXX	XXX
Gross Profit	$42.3M	$136M	XXX	XXX	XXX
Gross Margin	21%	48%	XXX	XXX	XXX
EBITDA	$20.6M	$77.5M	XXX	XXX	XXX
EBITDA Margin	10%	27%	XXX	XXX	XXX
Net Profit	-$87.4M	-$11.9M	XXX	XXX	XXX
Net Margin	-44%	-4%	XXX	XXX	XXX
Net Debt	$204M	$30.2M	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

MannKind Stock Performance

As of April 15, 2025, MannKind's stock price is $5.

MannKind has current market cap of $1.4B, and EV of $1.3B.

See MannKind trading valuation data

MannKind Stock Data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$1.3B	$1.4B	XXX	XXX	XXX	XXX	$0.12

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

MannKind Valuation Multiples

As of April 15, 2025, MannKind has market cap of $1.4B and EV of $1.3B.

MannKind's trades at 4.3x LTM EV/Revenue multiple, and n/a LTM EBITDA.

Analysts estimate MannKind's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

See valuation multiples for MannKind and 10K+ public comps

MannKind Financial Valuation Multiples

	FY 2024	FY 2025E	FY 2026E	FY 2027E
EV	$1.3B	XXX	XXX	XXX
EV/Revenue	4.4x	XXX	XXX	XXX
EV/EBITDA	16.2x	XXX	XXX	XXX
P/E	51.0x	XXX	XXX	XXX
P/E/Growth	0.7x	XXX	XXX	XXX
EV/FCF	38.3x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get MannKind Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

MannKind Valuation Multiples

MannKind's NTM/LTM revenue growth is 12%

MannKind's revenue per employee for the last fiscal year averaged $0.7M, while opex per employee averaged $0.3M for the same period.

Over next 12 months, MannKind's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .

Analysts estimate MannKind's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

See operational valuation multiples for MannKind and other 10K+ public comps

MannKind Operational Valuation Multiples

	FY 2024	NTM	FY 2025E	FY 2026E	FY 2027E
Revenue Growth	43%	XXX	XXX	XXX	XXX
EBITDA Margin	27%	XXX	XXX	XXX	XXX
EBITDA Growth	276%	XXX	XXX	XXX	XXX
Rule of 40 (SaaS-only)	39%	XXX	XXX	XXX	XXX
Revenue per Employee	$0.7M	XXX	XXX	XXX	XXX
Opex per Employee	$0.3M	XXX	XXX	XXX	XXX
S&M Expenses to Revenue	n/a	XXX	XXX	XXX	XXX
G&A Expenses to Revenue	n/a	XXX	XXX	XXX	XXX
R&D Expenses to Revenue	16%	XXX	XXX	XXX	XXX
Opex to Revenue	49%	XXX	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry